Edition:
United Kingdom

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

17.51USD
20 Aug 2018
Change (% chg)

$-0.39 (-2.18%)
Prev Close
$17.90
Open
$17.81
Day's High
$17.85
Day's Low
$17.43
Volume
14,635
Avg. Vol
252,022
52-wk High
$20.38
52-wk Low
$8.00

Latest Key Developments (Source: Significant Developments)

Karyopharm Completes Rolling Submission Of New Drug Application To FDA For Selinexor
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR SELINEXOR AS A TREATMENT FOR PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - KARYOPHARM PLANS TO COMMERCIALIZE SELINEXOR IN U..KARYOPHARM THERAPEUTICS- SHOULD APPLICATION BE APPROVED BY FDA, SELINEXOR COULD BECOME AVAILABLE IN H1 2019.KARYOPHARM THERAPEUTICS INC - PLANS TO SUBMIT MARKETING AUTHORIZATION APPLICATION TO EMA IN EARLY 2019.  Full Article

Karyopharm Initiates Rolling Submission Of New Drug Application To FDA For Selinexor
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM INITIATES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR SELINEXOR AS A TREATMENT FOR PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - COMPANY PLANS TO COMPLETE SUBMISSION DURING SECOND HALF OF 2018.KARYOPHARM THERAPEUTICS INC - PENDING MARKETING APPROVAL BY FDA, KARYOPHARM PLANS TO COMMERCIALIZE SELINEXOR IN U.S.  Full Article

Karyopharm Therapeutics Files For Potential Mixed Shelf; Size Not Disclosed
Monday, 2 Jul 2018 

July 2 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS FILES FOR POTENTIAL MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Karyopharm Therapeutics Says Offering Shares Of Common Stock With Aggregate Offering Price Of $125 Mln
Tuesday, 1 May 2018 

May 1 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS INC SAYS OFFERING SHARES OF CO'S COMMON STOCK WITH AN AGGREGATE OFFERING PRICE OF $125 MILLION - SEC FILING.  Full Article

Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 1 May 2018 

May 1 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.COMMENCEMENT OF A REGISTERED UNDERWRITTEN PUBLIC OFFERING OF $125 MILLION IN SHARES OF ITS COMMON STOCK.INTENDS TO USE NET PROCEEDS OF OFFERING TO SUPPORT CONTINUED CLINICAL DEVELOPMENT OF SELINEXOR.TO USE PROCEEDS OF OFFERING TO CONTINUE ESTABLISHING COMMERCIAL INFRASTRUCTURE FOR POTENTIAL LAUNCH OF SELINEXOR IN U.S..  Full Article

Karyopharm Therapeutics Says Co May Issue & Sell Shares Of Stock
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Karyopharm Therapeutics Inc ::KARYOPHARM THERAPEUTICS - CO MAY ISSUE & SELL SHARES OF STOCK, $0.0001 PAR VALUE PER SHARE, HAVING ADDITIONAL OFFERING PRICE OF UP TO $75 MILLION.KARYOPHARM THERAPEUTICS - ON DEC 1, CO ENTERED INTO AMENDMENT NO. 2 TO CONTROLLED EQUITY OFFERING SALES AGREEMENT, DATED DECEMBER 7, 2015 - SEC FILING.  Full Article

Point72 Asset Management L.P. reports 7.3 pct passive stake in Karyopharm Therapeutics Inc as of Nov. 3 - SEC filing‍​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Karyopharm Therapeutics Inc :Point72 Asset Management L.P. reports 7.3 percent passive stake in Karyopharm Therapeutics Inc as of November 3, 2017 - SEC filing‍​.  Full Article

Karyopharm Q3 loss per share $0.65
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Karyopharm Therapeutics Inc ::Karyopharm reports third quarter 2017 financial results and highlights recent progress.Q3 loss per share $0.65.Q3 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.Karyopharm Therapeutics Inc - ‍expect to report top-line results of phase 2b storm study by april 2018​.  Full Article

Wellington Management Group Llp reports 11.83 pct passive stake in Karyopharm
Tuesday, 11 Oct 2016 

:Wellington Management Group Llp reports passive stake of 11.83 percent in Karyopharm Therapeutics Inc as of Sept 30 - SEC Filing.  Full Article

Karyopharm Therapeutics provides update on Phase 2b STORM study
Tuesday, 30 Aug 2016 

Karyopharm Therapeutics Inc : Intends to expand its Phase 2b storm study evaluating activity of selinexor in multiple myeloma .Intends to expand its Phase 2b storm study to include approximately 120 additional patients with penta-refractory MM.  Full Article

BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78

* KARYOPHARM REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS